Discover investment opportunities in Top Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Psychedelic Stocks using our Smart AI Filter.
7 stocks found for "Top Psychedelic Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.17 | ±100.0% | -4.1 | 0.00% | |||
0.82 | ±100.0% | -13.0 | 0.00% | |||
1.28 | ±88.5% | -5.2 | 0.00% | |||
0.47 | ±100.0% | -0.9 | 0.00% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
1.02 | ±100.0% | -0.3 | 0.00% | |||
0.49 | ±66.7% | -1.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreThe average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read moreQ: What differentiates CMPS from other psychedelic stocks?
A: COMPASS Pathways (CMPS) focuses on developing psilocybin therapy for treatment-resistant depression. Their unique COMP360 psilocybin treatment is undergoing significant clinical trials, positioning CMPS as a key player in this niche sector.
Q: Is ATAI a good option for investors interested in diversified exposure to psychedelics?
A: ATAI Life Sciences (ATAI) is a bioscience company with a diversified approach, as it actively acquires, incubates, and supports various biotech companies, each exploring different compounds within the psychedelic space.
Q: What makes MNMD a noteworthy psychedelic stock for mental health treatment innovation?
A: MindMed (MNMD) explores a range of psychedelic substances, including LSD and MDMA, for treating mental health disorders. They aim to innovate by blending technology with psychedelic therapy.
Q: What potential growth factors are associated with investing in CYBN?
A: Cybin Inc. (CYBN) aims to revolutionize mental health treatment by improving the delivery of existing psilocybin therapies and developing new delivery methods, potentially broadening their market impact.
Q: How does GHRS appeal to investors interested in novel psychedelic applications?
A: GH Research PLC (GHRS) focuses on 5-MeO-DMT research for treating depression and other CNS disorders, differentiating it from other psychedelic companies primarily dealing with psilocybin and LSD.
Q: Can investors expect consistent income from RLMD through dividends?
A: Currently, Relmada Therapeutics Inc. (RLMD) does not offer dividends. The company is primarily focused on clinical development, so investors might prioritize potential growth over income generation.